Screener / SEC EDGAR /CIK 0001061983 /10-K filed Feb 26, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Cytokinetics Inc CYTK

Compare with peers Embed
Earnings releases

Latest results release: Nov 4, 2026

8-K item 2.02, exhibit 99

What CYTK's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Read and search

Every release, in full · linked to sec.gov

Press release Nov 4, 2026 · EX-99.1

Cytokinetics Reports Third Quarter 2026 Financial Results and Provides Business

Open on SEC

Exhibit 99.1 Cytokinetics Reports Third Quarter 2026 Financial Results and Provides Business Update

Expect to Submit Supplemental NDA for Aficamten in Non-Obstructive HCM in Q4 2026 and Type II Variation in the European Union in Early 2027

~$1.6 Billion in Cash, Cash Equivalents and Investments as of September 30, 2026 SOUTH SAN FRANCISCO, Calif., Nov. 4, 2026 -Cytokinetics, Incorporated (Nasdaq: CYTK) reported a management update and financial results for the third quarter of 2026.

“Our third quarter results demonstrate continued strong execution as Cytokinetics enters its next phase of growth as a global specialty cardiology biopharmaceutical company,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer. “In the U.S., the launch of MYQORZO continued to build solid momentum and increased velocity with growing adoption across a broadening base of prescribers. Internationally, we continued to expand access to MYQORZO to bring this important medicine to more patients around the world. Now, with our having presented and published the primary results from ACACIA-HCM, the first positive Phase 3 clinical trial in nHCM, we believeaficamtenhas the potential to become the first and only cardiac myosin inhibitor approved across the full spectrum of HCM. Building on these key results, we are moving swiftly to seek regulatory approvals in both the U.S. and Europe, important next steps toward achieving our Vision 2030.”

Continued to drive launch momentum for MYQORZO. Year-to-date (YTD) as of September 30, 2026:

MYQORZO received authorization from Health Canada for patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) of New York Heart Association (NYHA) class II-III in adult patients.

MYQORZO was granted marketing authorization across the United Kingdom by the Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of symptomatic oHCM of NYHA class II-III in adult patients. The National Institute for Health and Care Excellence (NICE) issued guidance recommending aficamten for use in eligible adult patients in England and Wales. We expect to launch MYQORZO in the United Kingdom in Q4 2026 and in additional countries in 2027.

Presented the positive primary results from ACACIA-HCM, the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM) in a Hot Line Session at the European Society of Cardiology Congress (ESC) and published in the New England Journal of Medicine . We expect to file a Supplemental New Drug Application (NDA) for nHCM in Q4 2026 and a Type II Variation in the European Union in early 2027.

Presented analyses from ACACIA-HCM and SEQUOIA-HCM at the HFSA Annual Scientific Meeting 2026, including two late-breaking presentations, further characterizing the efficacy and safety of aficamten in nHCM and oHCM.

Recently initiated ASPEN-HCM, a real-world study of MYQORZO in symptomatic oHCM.

Completed conduct of the main study treatment period of CAMELLIA-HCM, a Phase 3 clinical trial of aficamten in Japanese patients with oHCM. CAMELLIA-HCM is being conducted by Bayer in collaboration with Cytokinetics to support potential marketing authorization in Japan.

Recently completed conduct of the adolescent cohort of CEDAR-HCM, a clinical trial of aficamten in a pediatric population with symptomatic oHCM. We expect to present topline data in early 2027.

“Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy” in New England Journal of Medicine.

“Effect of Aficamten on Cardiac Structure and Function in Patients with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy” in Circulation .

“Efficacy of Aficamten vs Metoprolol According to Pretrial Beta-Blocker Treatment in Obstructive Hypertrophic Cardiomyopathy: Insights From MAPLE-HCM” in JACC: Heart Failure.

Continued conduct of COMET-HF, a confirmatory Phase 3 clinical trial of omecamtiv mecarbil in patients with symptomatic heart failure with severely reduced ejection fraction. We expect enrollment to continue through 2027.

Continued conduct of Cohort 1 of AMBER-HFpEF, a Phase 2 clinical trial of ulacamten in patients with symptomatic heart failure with preserved ejection fraction (HFpEF) with left ventricular ejection fraction (LVEF) ≥ 60%. We expect to complete patient enrollment in Cohort 1 in Q4 of 2026.

Continued conduct of the second Phase 1 randomized, double-blind, placebo- controlled single ascending dose clinical study of CK-4015089 (CK-089) in healthy human participants.

Achieved a preclinical development milestone under the 2025 research collaboration and license agreement with Accutar Biotech, triggering a $2.5 million payment to Accutar. The collaboration is focused on discovering and developing novel targeted protein degraders for muscle-related diseases.

Continued pre-clinical development and research activities directed to additional muscle biology focused programs.

As of September 30, 2026, the company had approximately $1.6 billion in cash, cash equivalents and investments compared to $1.7 billion at June 30, 2026.

Total revenues for the third quarter of 2026 were $47.6 million, compared to $1.9 million for the same period in 2025. Total revenues in the third quarter of 2026 include:

$44.5 million MYQORZO net product revenue, inclusive of $43.1 million from the U.S. and $1.4 million from Europe reflecting product revenue in Germany, and

$3.1 million in collaboration revenue compared to $1.9 million for the same period in 2025.

R&D expenses for the third quarter of 2026 were $99.3 million, which included $15.1 million of non-cash stock-based compensation expense, compared to $97.3 million for the same period in 2025, which included $15.1 million of non-cash stock-based compensation expense. The increase was primarily due to higher clinical trial activity and higher personnel-related costs.

SG&A expenses for the third quarter of 2026 were $113.1 million, which included $19.6 million of non-cash stock-based compensation expense, compared to $69.5 million for the same period in 2025, which included $15.6 million of non-cash stock-based compensation expense. The increase was primarily due to external costs associated with the commercial launch of MYQORZO and higher personnel- related costs, including stock-based compensation.

Cost of Goods Sold • Cost of goods sold related to MYQORZO for the third quarter of 2026 was ($0.5) million and reflects a credit related to drug supply optimization activities. Collaboration Cost of Revenues • Collaboration cost of revenues for the third quarter of 2026 was $2.7 million, compared to $1.9 million for the same period in 2025. Collaboration cost of revenues includes cost reimbursements as well as costs incurred in connection with manufacturing drug supplies for collaboration partners. Net Income (Loss) • Net loss for the third quarter of 2026 was $190.1 million, or $(1.37) per share, basic and diluted, compared to a net loss of $306.2 million, or $(2.55) per share, basic and diluted, for the same period in 2025. 2026 Financial Guidance The company is reaffirming its full year 2026 financial guidance:

GAAP combined R&D and SG&A Expense $860 million to $890 million Non-cash stock-based compensation expense included $140 million to $130 million in GAAP combined R&D and SG&A Expense

The financial guidance does not include the effect of GAAP adjustments as may be caused by events that occur subsequent to publication of this guidance including, but not limited to, Business Development activities. Conference Call and Webcast Information Members of Cytokinetics’ senior management team will review the company’s third quarter 2026 results on a conference call today at 4:30 PM Eastern Time. The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytokinetics’ website at www.cytokinetics.com or directly at the following link: Cytokinetics Q3 2026 Earnings Conference Call . An archived replay of the webcast will be available via Cytokinetics’ website for six months. About Cytokinetics Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO® ( aficamten ) is a cardiac myosin inhibitor approved in the U.S., China, European Union, United Kingdom and Canada for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Following positive results in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM (nHCM), the company plans to submit a Supplemental New Drug Application in Q4 2026. Cytokinetics is also developing omecamtiv mecarbil , an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten , an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology. For additional information about Cytokinetics, visitwww.cytokinetics.comand follow us onX,LinkedIn,FacebookandYouTube.

Omecamtiv mecarbil, ulacamtenand CK-089 are investigational medicines. They have not been approved nor determined to be safe or efficacious for any disease state or any indication by FDA or any other regulatory agency.

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics claims the protection of the Act’s Safe Harbor for forward-looking statements. All statements in this press release other than statements of historical fact are forward-looking statements. Words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “goal,” “intend,” “may,” “plan,” “potential,” “seek,” “should,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward- looking statements contain these identifying words. Examples of such statements include, but are not limited to, statements, express or implied, relating to our plans to submit a Supplemental NDA foraficamtenin non-obstructive HCM in the fourth quarter of 2026 and a Type II Variation in the European Union in early 2027, and the timing and outcome of any related regulatory review; our belief thataficamtenhas the potential to become the first and only cardiac myosin inhibitor approved across the full spectrum of HCM; the continued commercial launch of MYQORZO in the U.S., including launch momentum, prescriber adoption, patient uptake, market acceptance and net product revenue; our plans to launch MYQORZO in additional markets outside the U.S., including our expectation to launch in the United Kingdom in the fourth quarter of 2026 and in additional countries in 2027, and the timing and outcome of pending regulatory, pricing and reimbursement reviews in Switzerland, Hong Kong, Taiwan and other jurisdictions; our or our partners’ research and development and commercial readiness activities, including the initiation, conduct, design, enrollment, progress, continuation, completion, timing and results of any of our clinical trials, including ACACIA-HCM (including its Japan cohort), CAMELLIA-HCM, ASPEN-HCM, COMET-HF, AMBER-HFpEF and CEDAR-HCM and our clinical study of CK-089; our expectations to present topline data from the adolescent cohort of CEDAR-HCM in early 2027, to complete patient enrollment in Cohort 1 of AMBER-HFpEF in the fourth quarter of 2026 and to complete patient enrollment in COMET-HF in 2027; the clinical meaningfulness, persuasiveness, or interpretation of the results of MAPLE-HCM, SEQUOIA-HCM, ACACIA-HCM or any of our other clinical trials, including for purposes of regulatory approval, labeling, or market acceptance, the results of long-term, secondary or exploratory analyses, our ability to announce the results of any of our clinical trials by any particular date, the timing of interactions with FDA or any other regulatory authorities in connection with any of our drug candidates and the outcomes of such interactions; statements related to our receipt of regulatory approvals foraficamtenin any ex-US jurisdiction, including Japan, for any indication and by any particular date, statements relating to the potential patient population who could benefit fromaficamten,omecamtiv mecarbil,ulacamten, CK-089 or any of our other drug candidates; statements related to the potential approval and launch of MYQORZO in non-obstructive HCM; our research collaboration with Accutar Biotech and our other pre-clinical research activities, including any future milestone payments under such collaboration; our strategic goals, including our Vision 2030; our full year 2026 financial guidance, including our combined GAAP research and development and selling, general and administrative expense guidance and related non-cash stock-based compensation expense estimates, and the assumptions underlying such guidance; statements relating to our ability to receive additional capital or other funding, including, but not limited to, our ability to meet any of the conditions relating to or to otherwise secure additional loan disbursements under any of our agreements with entities affiliated with Royalty Pharma or additional milestone payments from Sanofi

or Bayer in connection with our collaborations foraficamtenin China or Japan respectively; statements relating to our operating expenses or cash utilization for the remainder of 2026 or any other period, and statements relating to our cash balance at any particular date or the amount of cash runway such cash balances represent at any particular time. Such statements are based on management's current expectations and assumptions, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: risks related to the commercialization of MYQORZO, including the degree of market acceptance among physicians, patients and payors, the availability of adequate coverage, pricing and reimbursement in the U.S. and other markets, our ability to maintain and expand our commercial capabilities and those of our partners, and fluctuations in net product revenue from period to period; competition from other cardiac myosin inhibitors and other existing or future therapies; the FDA or foreign regulatory agencies may not accept for review, or may delay, limit or deny approval of, our Supplemental NDA, Type II Variation or other marketing applications, or may require additional clinical trials or impose restrictive labeling or post-marketing requirements; the identification of new safety signals or adverse events relating to MYQORZO or our drug candidates as they are used more broadly; our dependence on third-party manufacturers and suppliers and on our collaboration and commercial partners, including Bayer and Sanofi, to perform their obligations; Cytokinetics’ need for additional funding and such additional funding may not be available on acceptable terms, if at all; our outstanding indebtedness and payment obligations, including under our agreements with entities affiliated with Royalty Pharma; potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics’ drug candidates that could slow or prevent clinical development or product approval; patient enrollment for or conduct of clinical trials may be difficult or delayed; the FDA or foreign regulatory agencies may delay or limit Cytokinetics’ or its partners’ ability to conduct clinical trials; Cytokinetics may incur unanticipated research and development, commercial and other costs; standards of care may change, rendering Cytokinetics’ drug candidates obsolete; competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics’ drug candidates and potential drug candidates may target; our ability to obtain, maintain and enforce intellectual property protection; and changes in laws, regulations or government policies affecting drug pricing, reimbursement, tariffs or trade, as well as general economic, market and geopolitical conditions. For further information regarding these and other risks related to Cytokinetics’ business, investors should consult Cytokinetics’ filings with the Securities and Exchange Commission, particularly under the caption “Risk Factors” in Cytokinetics’ Annual Report on Form 10-K for the year ended December 31, 2025 and its subsequent Quarterly Reports on Form 10-Q, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026. Forward-looking statements are not guarantees of future performance, and Cytokinetics’ actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Except as required by law, Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CYTOKINETICS®and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

MYQORZO®is a registered trademark of Cytokinetics in the U.S., European Union, United Kingdom and Canada.

Cytokinetics, Incorporated Condensed Consolidated Balance Sheets (in thousands) September 30, 2026 December 31, 2025 -unaudited ASSETS Current assets: Cash and short term $ $ investments 1,130,021 882,221 Other current assets 57,130 34,754 Total current assets 1,187,151 916,975 Long-term investments 453,631 335,048 Property and 76,124 79,194 equipment, net Operating lease 71,563 75,979 right-of-use assets Inventories, long-term 16,128 — Other assets 20,183 17,341 Total assets $ $ 1,824,780 1,424,537 LIABILITIES AND STOCKHOLDERS’ DEFICIT Current liabilities: Accounts payable and $ $ accrued liabilities 116,835 105,615 Short-term operating 21,391 19,111 lease liabilities Current portion of convertible and 174,399 41,181 long-term debt Derivative liabilities measured at fair 31,300 31,100 value Deferred revenue 1,653 1,612 Other current 7,841 3,833 liabilities Total current 353,419 202,452 liabilities Term loan, net 244,332 246,384 Convertible notes, net 732,771 869,597 Liabilities related to revenue participation right 579,564 520,559 purchase agreements, net Long-term operating 99,665 107,970 lease liabilities Liabilities related to RPI Transactions 136,200 137,200 measured at fair value Total liabilities 2,145,951 2,084,162 Commitments and contingencies Stockholders' deficit Common stock 139 123 Additional paid-in 3,768,661 2,826,341 capital Accumulated other comprehensive (loss) -8,390 630 income Accumulated deficit -4,081,581 -3,486,719 Total stockholders' -321,171 -659,625 deficit Total liabilities and $ $ stockholders' 1,824,780 1,424,537 deficit

Cytokineti… Incorporat… Condensed Consolidat… Statements of Operations (in thousands except per share data) (unaudited) Three Months Nine Months Ended Ended September September September September 30, 30, 2026 30, 2025 30, 2026 2025 Revenues: Net product $ $ $ $ revenue 44,507 — 74,630 — Collaborat… 3,050 1,936 8,977 5,931 revenues License and milestone - — 11,929 64,353 revenues Total 47,557 1,936 95,536 70,284 revenues Operating expenses: Research and 99,285 97,297 292,617 305,697 development Selling, general and 113,144 69,458 322,437 192,548 administra… Cost of -454 — 2,437 — goods sold Collaborat… cost of 2,670 1,936 7,923 5,931 revenues Total operating 214,645 168,691 625,414 504,176 expenses Operating -167,088 -166,755 -529,878 -433,892 loss Interest and other -14,842 -11,353 -44,015 -31,305 expense, net Non-cash interest expense on liabilities related to -23,642 -14,969 -62,635 -42,228 revenue participat… right purchase agreements Interest and other 15,903 10,248 40,866 36,950 income, net Change in fair value of -600 700 -200 3,300 derivative liabilities Change in fair value of liabilities 200 -2,800 1,000 -13,500 related to RPI Transactio… Debt conversion — -121,249 — -121,249 expense Net loss $ $ $ $ (190,069) (306,178) (594,862) (601,924) Net loss per share — $ $ $ $ basic and (1.37) (2.55) (4.52) (5.04) diluted Weighted-a… number of shares used in computing 139,045 119,982 131,526 119,317 net loss per share — basic and diluted

Full text with the tables
                                                                    Exhibit 99.1
Cytokinetics Reports Third Quarter 2026 Financial Results and Provides Business 
                                     Update                                     
                                                                                
            MYQORZO®(aficamten) Net Product Revenue of $44.5 Million            
                                                                                
  Expect to Submit Supplemental NDA for Aficamten in Non-Obstructive HCM in Q4  
         2026 and Type II Variation in the European Union in Early 2027         
                                                                                
~$1.6 Billion in Cash, Cash Equivalents and Investments as of September 30, 2026
SOUTH SAN FRANCISCO, Calif., Nov. 4, 2026 -Cytokinetics, Incorporated (Nasdaq:
CYTK) reported a management update and financial results for the third quarter
of 2026.

“Our third quarter results demonstrate continued strong execution as
Cytokinetics enters its next phase of growth as a global specialty cardiology
biopharmaceutical company,” said Robert I. Blum, Cytokinetics’ President and
Chief Executive Officer. “In the U.S., the launch of MYQORZO continued to build
solid momentum and increased velocity with growing adoption across a broadening
base of prescribers. Internationally, we continued to expand access to MYQORZO
to bring this important medicine to more patients around the world. Now, with
our having presented and published the primary results from ACACIA-HCM, the
first positive Phase 3 clinical trial in nHCM, we believeaficamtenhas the
potential to become the first and only cardiac myosin inhibitor approved across
the full spectrum of HCM. Building on these key results, we are moving swiftly
to seek regulatory approvals in both the U.S. and Europe, important next steps
toward achieving our Vision 2030.”

Q3 and Recent Highlights

Cardiac Muscle Programs

MYQORZO®(aficamten)(cardiac myosin inhibitor)

Continued to drive launch momentum for MYQORZO. Year-to-date (YTD) as of
September 30, 2026:

Nearly 1,100 unique healthcare providers have prescribed MYQORZO.

Over 2,800 patients have been dispensed MYQORZO.

MYQORZO received authorization from Health Canada for patients with symptomatic
obstructive hypertrophic cardiomyopathy (oHCM) of New York Heart Association
(NYHA) class II-III in adult patients.

MYQORZO was granted marketing authorization across the United Kingdom by the
Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of
symptomatic oHCM of NYHA class II-III in adult patients. The National Institute
for Health and Care Excellence (NICE) issued guidance recommending aficamten for
use in eligible adult patients in England and Wales. We expect to launch MYQORZO
in the United Kingdom in Q4 2026 and in additional countries in 2027.

Presented the positive primary results from ACACIA-HCM, the pivotal Phase 3
clinical trial of aficamten in patients with symptomatic non-obstructive
hypertrophic cardiomyopathy (nHCM) in a Hot Line Session at the European Society
of Cardiology Congress (ESC) and published in the New England Journal of
Medicine . We expect to file a Supplemental New Drug Application (NDA) for nHCM
in Q4 2026 and a Type II Variation in the European Union in early 2027.

Presented analyses from ACACIA-HCM and SEQUOIA-HCM at the HFSA Annual Scientific
Meeting 2026, including two late-breaking presentations, further characterizing
the efficacy and safety of aficamten in nHCM and oHCM.

Advanced the ongoing clinical trials program for aficamten:

Recently initiated ASPEN-HCM, a real-world study of MYQORZO in symptomatic oHCM.

Completed conduct of the main study treatment period of CAMELLIA-HCM, a Phase 3
clinical trial of aficamten in Japanese patients with oHCM. CAMELLIA-HCM is
being conducted by Bayer in collaboration with Cytokinetics to support potential
marketing authorization in Japan.

Recently completed conduct of the Japan cohort of ACACIA-HCM.

Recently completed conduct of the adolescent cohort of CEDAR-HCM, a clinical
trial of aficamten in a pediatric population with symptomatic oHCM. We expect to
present topline data in early 2027.

Published the following manuscripts:

“Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy” in New
England Journal of Medicine.

“Effect of Aficamten on Cardiac Structure and Function in Patients with
Symptomatic Nonobstructive Hypertrophic Cardiomyopathy” in Circulation .

“Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy:
Results From ACACIA-HCM” in Circulation .

“Efficacy of Aficamten vs Metoprolol According to Pretrial Beta-Blocker
Treatment in Obstructive Hypertrophic Cardiomyopathy: Insights From MAPLE-HCM”
in JACC: Heart Failure.

omecamtiv mecarbil(cardiac myosin activator)

Continued conduct of COMET-HF, a confirmatory Phase 3 clinical trial of
omecamtiv mecarbil in patients with symptomatic heart failure with severely
reduced ejection fraction. We expect enrollment to continue through 2027.

ulacamten(cardiac myosin inhibitor)

Continued conduct of Cohort 1 of AMBER-HFpEF, a Phase 2 clinical trial of
ulacamten in patients with symptomatic heart failure with preserved ejection
fraction (HFpEF) with left ventricular ejection fraction (LVEF) ≥ 60%. We expect
to complete patient enrollment in Cohort 1 in Q4 of 2026.

CK-4015089(CK-089, fast skeletal muscle troponin activator)

Continued conduct of the second Phase 1 randomized, double-blind, placebo-
controlled single ascending dose clinical study of CK-4015089 (CK-089) in
healthy human participants.

Pre-Clinical Development and Ongoing Research

Achieved a preclinical development milestone under the 2025 research
collaboration and license agreement with Accutar Biotech, triggering a $2.5
million payment to Accutar. The collaboration is focused on discovering and
developing novel targeted protein degraders for muscle-related diseases.

Continued pre-clinical development and research activities directed to
additional muscle biology focused programs.

Q3 2026 Financial Results

Cash, Cash Equivalents and Investments

As of September 30, 2026, the company had approximately $1.6 billion in cash,
cash equivalents and investments compared to $1.7 billion at June 30, 2026.

Revenues

Total revenues for the third quarter of 2026 were $47.6 million, compared to
$1.9 million for the same period in 2025. Total revenues in the third quarter of
2026 include:

$44.5 million MYQORZO net product revenue, inclusive of $43.1 million from the
U.S. and $1.4 million from Europe reflecting product revenue in Germany, and

$3.1 million in collaboration revenue compared to $1.9 million for the same
period in 2025.

Research and Development (R&D) Expenses

R&D expenses for the third quarter of 2026 were $99.3 million, which included
$15.1 million of non-cash stock-based compensation expense, compared to $97.3
million for the same period in 2025, which included $15.1 million of non-cash
stock-based compensation expense. The increase was primarily due to higher
clinical trial activity and higher personnel-related costs.

Selling, General and Administrative (SG&A) Expenses

SG&A expenses for the third quarter of 2026 were $113.1 million, which included
$19.6 million of non-cash stock-based compensation expense, compared to $69.5
million for the same period in 2025, which included $15.6 million of non-cash
stock-based compensation expense. The increase was primarily due to external
costs associated with the commercial launch of MYQORZO and higher personnel-
related costs, including stock-based compensation.

Cost of Goods Sold
• Cost of goods sold related to MYQORZO for the third quarter of 2026 was ($0.5)
million and reflects a credit related to drug supply optimization activities.
Collaboration Cost of Revenues • Collaboration cost of revenues for the third
quarter of 2026 was $2.7 million, compared to $1.9 million for the same period
in 2025. Collaboration cost of revenues includes cost reimbursements as well as
costs incurred in connection with manufacturing drug supplies for collaboration
partners. Net Income (Loss) • Net loss for the third quarter of 2026 was $190.1
million, or $(1.37) per share, basic and diluted, compared to a net loss of
$306.2 million, or $(2.55) per share, basic and diluted, for the same period in
2025. 2026 Financial Guidance The company is reaffirming its full year 2026
financial guidance:
                                                                                
  GAAP combined R&D and SG&A Expense              $860 million to $890 million  
  Non-cash stock-based compensation expense                                     
  included                                        $140 million to $130 million  
  in GAAP combined R&D and SG&A Expense                                         
                                                                                
The financial guidance does not include the effect of GAAP adjustments as may be
caused by events that occur subsequent to publication of this guidance
including, but not limited to, Business Development activities. Conference Call
and Webcast Information Members of Cytokinetics’ senior management team will
review the company’s third quarter 2026 results on a conference call today at
4:30 PM Eastern Time. The conference call will be simultaneously webcast and can
be accessed from the Investors & Media section of Cytokinetics’ website at
www.cytokinetics.com or directly at the following link: Cytokinetics Q3 2026
Earnings Conference Call . An archived replay of the webcast will be available
via Cytokinetics’ website for six months. About Cytokinetics Cytokinetics is a
specialty cardiovascular biopharmaceutical company, building on its over 25
years of pioneering scientific innovations in muscle biology, and advancing a
pipeline of potential new medicines for patients suffering from diseases of
cardiac muscle dysfunction. Cytokinetics’ MYQORZO® ( aficamten ) is a cardiac
myosin inhibitor approved in the U.S., China, European Union, United Kingdom and
Canada for the treatment of adults with symptomatic obstructive hypertrophic
cardiomyopathy (oHCM). Following positive results in ACACIA-HCM, a Phase 3
clinical trial of aficamten in patients with non-obstructive HCM (nHCM), the
company plans to submit a Supplemental New Drug Application in Q4 2026.
Cytokinetics is also developing omecamtiv mecarbil , an investigational cardiac
myosin activator for the potential treatment of patients with heart failure with
severely reduced ejection fraction and ulacamten , an investigational cardiac
myosin inhibitor for the potential treatment of heart failure with preserved
ejection fraction, while continuing pre-clinical research and development in
muscle biology.
For additional information about Cytokinetics, visitwww.cytokinetics.comand
follow us onX,LinkedIn,FacebookandYouTube.

Disclaimer

Omecamtiv mecarbil, ulacamtenand CK-089 are investigational medicines. They have
not been approved nor determined to be safe or efficacious for any disease state
or any indication by FDA or any other regulatory agency.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the
Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics
claims the protection of the Act’s Safe Harbor for forward-looking statements.
All statements in this press release other than statements of historical fact
are forward-looking statements. Words such as “anticipate,” “believe,”
“continue,” “could,” “estimate,” “expect,” “goal,” “intend,” “may,” “plan,”
“potential,” “seek,” “should,” “will,” “would” and similar expressions are
intended to identify forward-looking statements, although not all forward-
looking statements contain these identifying words. Examples of such statements
include, but are not limited to, statements, express or implied, relating to our
plans to submit a Supplemental NDA foraficamtenin non-obstructive HCM in the
fourth quarter of 2026 and a Type II Variation in the European Union in early
2027, and the timing and outcome of any related regulatory review; our belief
thataficamtenhas the potential to become the first and only cardiac myosin
inhibitor approved across the full spectrum of HCM; the continued commercial
launch of MYQORZO in the U.S., including launch momentum, prescriber adoption,
patient uptake, market acceptance and net product revenue; our plans to launch
MYQORZO in additional markets outside the U.S., including our expectation to
launch in the United Kingdom in the fourth quarter of 2026 and in additional
countries in 2027, and the timing and outcome of pending regulatory, pricing and
reimbursement reviews in Switzerland, Hong Kong, Taiwan and other jurisdictions;
our or our partners’ research and development and commercial readiness
activities, including the initiation, conduct, design, enrollment, progress,
continuation, completion, timing and results of any of our clinical trials,
including ACACIA-HCM (including its Japan cohort), CAMELLIA-HCM, ASPEN-HCM,
COMET-HF, AMBER-HFpEF and CEDAR-HCM and our clinical study of CK-089; our
expectations to present topline data from the adolescent cohort of CEDAR-HCM in
early 2027, to complete patient enrollment in Cohort 1 of AMBER-HFpEF in the
fourth quarter of 2026 and to complete patient enrollment in COMET-HF in 2027;
the clinical meaningfulness, persuasiveness, or interpretation of the results of
MAPLE-HCM, SEQUOIA-HCM, ACACIA-HCM or any of our other clinical trials,
including for purposes of regulatory approval, labeling, or market acceptance,
the results of long-term, secondary or exploratory analyses, our ability to
announce the results of any of our clinical trials by any particular date, the
timing of interactions with FDA or any other regulatory authorities in
connection with any of our drug candidates and the outcomes of such
interactions; statements related to our receipt of regulatory approvals
foraficamtenin any ex-US jurisdiction, including Japan, for any indication and
by any particular date, statements relating to the potential patient population
who could benefit fromaficamten,omecamtiv mecarbil,ulacamten, CK-089 or any of
our other drug candidates; statements related to the potential approval and
launch of MYQORZO in non-obstructive HCM; our research collaboration with
Accutar Biotech and our other pre-clinical research activities, including any
future milestone payments under such collaboration; our strategic goals,
including our Vision 2030; our full year 2026 financial guidance, including our
combined GAAP research and development and selling, general and administrative
expense guidance and related non-cash stock-based compensation expense
estimates, and the assumptions underlying such guidance; statements relating to
our ability to receive additional capital or other funding, including, but not
limited to, our ability to meet any of the conditions relating to or to
otherwise secure additional loan disbursements under any of our agreements with
entities affiliated with Royalty Pharma or additional milestone payments from
Sanofi

or Bayer in connection with our collaborations foraficamtenin China or Japan
respectively; statements relating to our operating expenses or cash utilization
for the remainder of 2026 or any other period, and statements relating to our
cash balance at any particular date or the amount of cash runway such cash
balances represent at any particular time. Such statements are based on
management's current expectations and assumptions, but actual results may differ
materially due to various risks and uncertainties, including, but not limited
to: risks related to the commercialization of MYQORZO, including the degree of
market acceptance among physicians, patients and payors, the availability of
adequate coverage, pricing and reimbursement in the U.S. and other markets, our
ability to maintain and expand our commercial capabilities and those of our
partners, and fluctuations in net product revenue from period to period;
competition from other cardiac myosin inhibitors and other existing or future
therapies; the FDA or foreign regulatory agencies may not accept for review, or
may delay, limit or deny approval of, our Supplemental NDA, Type II Variation or
other marketing applications, or may require additional clinical trials or
impose restrictive labeling or post-marketing requirements; the identification
of new safety signals or adverse events relating to MYQORZO or our drug
candidates as they are used more broadly; our dependence on third-party
manufacturers and suppliers and on our collaboration and commercial partners,
including Bayer and Sanofi, to perform their obligations; Cytokinetics’ need for
additional funding and such additional funding may not be available on
acceptable terms, if at all; our outstanding indebtedness and payment
obligations, including under our agreements with entities affiliated with
Royalty Pharma; potential difficulties or delays in the development, testing,
regulatory approvals for trial commencement, progression or product sale or
manufacturing, or production of Cytokinetics’ drug candidates that could slow or
prevent clinical development or product approval; patient enrollment for or
conduct of clinical trials may be difficult or delayed; the FDA or foreign
regulatory agencies may delay or limit Cytokinetics’ or its partners’ ability to
conduct clinical trials; Cytokinetics may incur unanticipated research and
development, commercial and other costs; standards of care may change, rendering
Cytokinetics’ drug candidates obsolete; competitive products or alternative
therapies may be developed by others for the treatment of indications
Cytokinetics’ drug candidates and potential drug candidates may target; our
ability to obtain, maintain and enforce intellectual property protection; and
changes in laws, regulations or government policies affecting drug pricing,
reimbursement, tariffs or trade, as well as general economic, market and
geopolitical conditions. For further information regarding these and other risks
related to Cytokinetics’ business, investors should consult Cytokinetics’
filings with the Securities and Exchange Commission, particularly under the
caption “Risk Factors” in Cytokinetics’ Annual Report on Form 10-K for the year
ended December 31, 2025 and its subsequent Quarterly Reports on Form 10-Q,
including its Quarterly Report on Form 10-Q for the quarter ended September 30,
2026. Forward-looking statements are not guarantees of future performance, and
Cytokinetics’ actual results of operations, financial condition and liquidity,
and the development of the industry in which it operates, may differ materially
from the forward-looking statements contained in this press release. Any
forward-looking statements that Cytokinetics makes in this press release speak
only as of the date of this press release. Except as required by law,
Cytokinetics assumes no obligation to update its forward-looking statements
whether as a result of new information, future events or otherwise, after the
date of this press release.

CYTOKINETICS®and the CYTOKINETICS C-shaped logo are registered trademarks of
Cytokinetics in the U.S. and certain other countries.

MYQORZO®is a registered trademark of Cytokinetics in the U.S., European Union,
United Kingdom and Canada.

###

Contact:

Cytokinetics

Diane Weiser

Senior Vice President, Corporate Affairs

(415) 290-7757
                                                                                
  Cytokinetics,                                                                 
  Incorporated                                                                  
  Condensed Consolidated                                                        
  Balance Sheets                                                                
  (in thousands)                                                                
                                 September 30, 2026          December 31, 2025  
                                         -unaudited                             
  ASSETS                                                                        
  Current assets:                                                               
  Cash and short term                             $                          $  
  investments                             1,130,021                    882,221  
  Other current assets                       57,130                     34,754  
  Total current assets                    1,187,151                    916,975  
  Long-term investments                     453,631                    335,048  
  Property and                               76,124                     79,194  
  equipment, net                                                                
  Operating lease                            71,563                     75,979  
  right-of-use assets                                                           
  Inventories, long-term                     16,128                          —  
  Other assets                               20,183                     17,341  
  Total assets                                    $                          $  
                                          1,824,780                  1,424,537  
  LIABILITIES AND                                                               
  STOCKHOLDERS’ DEFICIT                                                         
  Current liabilities:                                                          
  Accounts payable and                            $                          $  
  accrued liabilities                       116,835                    105,615  
  Short-term operating                       21,391                     19,111  
  lease liabilities                                                             
  Current portion of                                                            
  convertible and                           174,399                     41,181  
  long-term debt                                                                
  Derivative liabilities                                                        
  measured at fair                           31,300                     31,100  
  value                                                                         
  Deferred revenue                            1,653                      1,612  
  Other current                               7,841                      3,833  
  liabilities                                                                   
  Total current                             353,419                    202,452  
  liabilities                                                                   
  Term loan, net                            244,332                    246,384  
  Convertible notes, net                    732,771                    869,597  
  Liabilities related to                                                        
  revenue                                                                       
  participation right                       579,564                    520,559  
  purchase agreements,                                                          
  net                                                                           
  Long-term operating                        99,665                    107,970  
  lease liabilities                                                             
  Liabilities related to                                                        
  RPI Transactions                          136,200                    137,200  
  measured at fair value                                                        
  Total liabilities                       2,145,951                  2,084,162  
  Commitments and                                                               
  contingencies                                                                 
  Stockholders' deficit                                                         
  Common stock                                  139                        123  
  Additional paid-in                      3,768,661                  2,826,341  
  capital                                                                       
  Accumulated other                                                             
  comprehensive (loss)                       -8,390                        630  
  income                                                                        
  Accumulated deficit                    -4,081,581                 -3,486,719  
  Total stockholders'                      -321,171                   -659,625  
  deficit                                                                       
  Total liabilities and                           $                          $  
  stockholders'                           1,824,780                  1,424,537  
  deficit                                                                       
                                                                                
                                                                                
  Cytokineti…                                                                   
  Incorporat…                                                                   
  Condensed                                                                     
  Consolidat…                                                                   
  Statements                                                                    
  of                                                                            
  Operations                                                                    
  (in                                                                           
  thousands                                                                     
  except per                                                                    
  share data)                                                                   
  (unaudited)                                                                   
                 Three Months                     Nine Months                   
                        Ended                           Ended                   
                    September       September       September    September 30,  
                     30, 2026        30, 2025        30, 2026             2025  
  Revenues:                                                                     
  Net product               $               $               $                $  
  revenue              44,507               —          74,630                —  
  Collaborat…           3,050           1,936           8,977            5,931  
  revenues                                                                      
  License and                                                                   
  milestone                 -               —          11,929           64,353  
  revenues                                                                      
  Total                47,557           1,936          95,536           70,284  
  revenues                                                                      
  Operating                                                                     
  expenses:                                                                     
  Research                                                                      
  and                  99,285          97,297         292,617          305,697  
  development                                                                   
  Selling,                                                                      
  general and         113,144          69,458         322,437          192,548  
  administra…                                                                   
  Cost of                -454               —           2,437                —  
  goods sold                                                                    
  Collaborat…                                                                   
  cost of               2,670           1,936           7,923            5,931  
  revenues                                                                      
  Total                                                                         
  operating           214,645         168,691         625,414          504,176  
  expenses                                                                      
  Operating          -167,088        -166,755        -529,878         -433,892  
  loss                                                                          
  Interest                                                                      
  and other           -14,842         -11,353         -44,015          -31,305  
  expense,                                                                      
  net                                                                           
  Non-cash                                                                      
  interest                                                                      
  expense on                                                                    
  liabilities                                                                   
  related to          -23,642         -14,969         -62,635          -42,228  
  revenue                                                                       
  participat…                                                                   
  right                                                                         
  purchase                                                                      
  agreements                                                                    
  Interest                                                                      
  and other            15,903          10,248          40,866           36,950  
  income, net                                                                   
  Change in                                                                     
  fair value                                                                    
  of                     -600             700            -200            3,300  
  derivative                                                                    
  liabilities                                                                   
  Change in                                                                     
  fair value                                                                    
  of                                                                            
  liabilities             200          -2,800           1,000          -13,500  
  related to                                                                    
  RPI                                                                           
  Transactio…                                                                   
  Debt                                                                          
  conversion                —        -121,249               —         -121,249  
  expense                                                                       
  Net loss                  $               $               $                $  
                    (190,069)       (306,178)       (594,862)        (601,924)  
  Net loss                                                                      
  per share —               $               $               $                $  
  basic and            (1.37)          (2.55)          (4.52)           (5.04)  
  diluted                                                                       
  Weighted-a…                                                                   
  number of                                                                     
  shares used                                                                   
  in                                                                            
  computing           139,045         119,982         131,526          119,317  
  net loss                                                                      
  per share —                                                                   
  basic                                                                         
  and diluted                                                                   
                                                                                

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/CYTK/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.